Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report
暂无分享,去创建一个
H. E. Meyer zu Schwabedissen | T. Mikoteit | M. Hatzinger | K. Hersberger | Markus L Lampert | Markus L. Lampert | Céline K. Stäuble | Henriette E. Meyer zu Schwabedissen
[1] H. E. Meyer zu Schwabedissen,et al. Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions , 2021, Pharmacogenomics and personalized medicine.
[2] H. E. Meyer zu Schwabedissen,et al. Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report. , 2020, Pharmacogenomics.
[3] Julia M. Barbarino,et al. Pharmacogenetic information in Swiss drug labels – a systematic analysis , 2020, The Pharmacogenomics Journal.
[4] H. Guchelaar,et al. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review , 2020, Journal of clinical medicine.
[5] A. Cross,et al. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models , 2016, British journal of pharmacology.
[6] E. Molden,et al. Impact of Genetic Variability in CYP2D6, CYP3A5, and ABCB1 on Serum Concentrations of Quetiapine and N-desalkylquetiapine in Psychiatric Patients , 2015, Therapeutic drug monitoring.
[7] R. Grohmann,et al. Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. , 2013, Swiss medical weekly.
[8] E. Molden,et al. Metabolism of the Active Metabolite of Quetiapine, N-Desalkylquetiapine In Vitro , 2012, Drug Metabolism and Disposition.
[9] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.
[10] H. Refsum,et al. Pharmacokinetic Variability of Quetiapine and the Active Metabolite N-desalkylquetiapine in Psychiatric Patients , 2011, Therapeutic drug monitoring.
[11] Bryan L Roth,et al. N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity , 2008, Neuropsychopharmacology.
[12] D. Greenblatt,et al. Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers , 2007, Journal of clinical psychopharmacology.
[13] L. Brauer,et al. Inhibition of CYP2D6 Activity by Bupropion , 2005, Journal of clinical psychopharmacology.
[14] E. Rüther,et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. , 2004, Pharmacopsychiatry.
[15] E. Rüther,et al. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. , 2004, Pharmacopsychiatry.
[16] J S Harmatz,et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[17] S. Kapur,et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. , 2000, Archives of general psychiatry.
[18] S. Grimm,et al. 559 In vitro prediction of potential metabolic drug interactions for seroquel , 1997, Schizophrenia Research.
[19] S. Hirsch,et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. , 1997, Archives of general psychiatry.
[20] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[21] H. M. Z. Schwabedissen,et al. The Role of Pharmacogenomics in Individualized Medicine , 2015 .
[22] S. Grimm,et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. , 2006, British journal of clinical pharmacology.
[23] C. Saller,et al. Seroquel: biochemical profile of a potential atypical antipsychotic , 2005, Psychopharmacology.
[24] C. Nemeroff,et al. Clinical Pharmacokinetics of Quetiapine , 2001, Clinical pharmacokinetics.
[25] M. Bergström,et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia , 1998, Psychopharmacology.
[26] A. Beck,et al. Assessment of depression: the depression inventory. , 1974, Modern problems of pharmacopsychiatry.